"uuid:ID","description","rationale","name","label","instanceType","id"
"5dd9ba84-0d72-4653-a80e-b3d8526d6b2c","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Study Design 1","","StudyDesign","StudyDesign_1"
